Results 221 to 230 of about 103,365 (348)

High molecular thyrotrophin ("big"-TSH) from human pituitaries : Preparation and partial characterization [PDF]

, 1977
Erhardt, F., Scriba, Peter Christian
core   +1 more source

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. [PDF]

ACR Open Rheumatol
Kellner DA, Dente E, Tran V, Welsh T, Tran V, Saha A, Baker JF, Elashoff DA, Ranganath VK.   +8 more
europepmc   +1 more source

Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists? [PDF]

, 2017
Cristian Guja, Rucsandra Dănciulescu Miulescu   +1 more
openalex   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework. [PDF]

Cancer Med
Dalbeni A, Vicardi M, Natola LA, Cattazzo F, Auriemma A, Lombardi R, Cinque F, Dalle Carbonare L, Mantovani A, Sacerdoti D.   +9 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review

Matt Thomas, Svetlana Mastitskaya, Samuel Parker, Ruth Cookson, Lucy Holmes, Aidan Marsh, Aravind Ramesh, Sarah Rudd, Mario Teo, Alex Mortimer   +9 more
openalex   +1 more source

Examining the Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Human Gut Microbiome: A Systematic Review [PDF]

Hezekiah C.T. Au, Kwun M. Fong, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, William W. L. Cheung, Kyle Valentino, Bing Cao, Heidi Ka Ying Lo, Roger Ho, Roger S. McIntyre   +11 more
openalex   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, EarlyView.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source